DAIICHI-SANKYO
Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) today announced the launch of the Future of Heart Health in Europe: A Holistic Care Think Tank report. The report follows the first-of-its-kind holistic care Think Tank meeting, held earlier this year, which brought together influential representatives from various disciplines including clinicians, patient advocates, researchers, digital and media experts and policy specialists. Three strategic recommendations for incorporating a holistic approach to CV care in Europe arose from the meeting:
-
Improve lifelong support and education:
- Improving lifelong support and education from a young age to lay a strong foundation for sustained wellness; introducing programmes in the workplace that reward physical and mental well-being.
-
Increase interdisciplinary collaboration and communication:
- Assigning a patient case manager and embracing implementation of artificial intelligence to improve communication and coordination of interdisciplinary collaboration.
-
Changes in health policies across Europe:
- A holistic view of CV care should be included on political agendas at a European level. Policy changes will lead to better access to preventative care, support for the adoption of a healthy lifestyle, and removal of barriers to equitable healthcare.
Across Europe, CVD is responsible for the loss of 10,000 lives every day.3 However, cardiovascular conditions are largely preventable, and there is a growing emphasis on addressing the burden of CVD through behavioural changes and risk factor management. The holistic care Think Tank included experts with a focus on behavioural and physiological factors for CVD, such as diet, exercise, and mental health. These experts play a vital role in raising awareness of the various aspects of CVD and, together, can build a more holistic picture of a person’s health that goes beyond the view of the heart alone.
"Collaborating with a diverse array of stakeholders is paramount in adopting a truly holistic approach to heart health in Europe,” said Berk Kiran, Vice President, Commercial Operations Europe, Daiichi Sankyo Europe. “By harnessing the unique perspectives and expertise of individuals across disciplines, sectors, and backgrounds, we can help forge innovative solutions that address the challenges facing cardiovascular health today. Together, we can drive meaningful change and pave the way towards a healthier future for all."
“At a political level, I think that it's time to establish health promotion and cardiovascular prevention as a real priority,” said Professor Hélder Dores, Cardiologist, Portugal and member of the Think Tank. “In healthcare, I think that not only for cardiologists but for all the professionals, it’s important to amend how we’re determining an individual’s risk and to improve lifestyle, because as we know, the great majority of atherosclerotic events could be prevented if we address the underlying risk factors.”
The inaugural Think Tank meeting and report form part of Daiichi Sankyo’s ongoing heart health initiative: We Care for Every Heartbeat (WC4EHB).
For further information on holistic approaches to CV health and care in Europe and to read the full report please visit our WC4EHB website: https://wecareforeveryheartbeat.com/.
-ENDS-
About We Care for Every Heartbeat
At Daiichi Sankyo we care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. Under the WC4EHB umbrella, Daiichi Sankyo regularly publishes informational blogs designed to improve health literacy and CVD care across Europe. We have conducted awareness surveys to uncover the public perception and attitude towards heart disease. We are working with external organisations, such as The Economist and the European Nutrition for Health Alliance (ENHA), to better understand the burden of CVD in Europe, and we partner with health specialists across a range of CV-relevant professions to advocate for greater collaboration and a holistic approach in Europe. We have made a long-term commitment to invest and work tirelessly to help patients and inspire positive change in CV care. For further information on WC4EHB and our activities, visit our website: https://wecareforeveryheartbeat.com/.
About CVD in Europe
CVD – a group of disorders affecting the heart and circulatory system, which can lead to heart attacks and strokes – is the primary cause of death in Europe, accounting for 45% of all deaths in the region and responsible for more than 10,000 lives lost every day.3,4,5,6 Furthermore, a large proportion of these deaths are premature – occurring before the age of 65 years – with CVD responsible for almost a quarter of premature deaths among men and nearly a fifth among women in Europe.7 Despite its high prevalence and burden, a lack of public awareness and gaps in understanding, especially of CVD risk factors, may be preventing those at risk from making positive lifestyle changes and adopting healthy habits to help reduce their CVD risk.8
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.
For more information, please visit www.daiichisankyo.com
| References |
_____________________________ |
1 World Health Organization. Cardiovascular Diseases (CVDs) Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed May 2024. |
2 Luengo-Fernandez, R., et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023. 00: 1–16. |
3 Mach, F., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020. 41;(1): 111–188. |
4 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Available at: https://ehnheart.org/wp-content/uploads/2023/07/CVD-Statistics.pdf. Last accessed May 2024. |
5 European Heart Network. CVD Statistics. Available at: https://ehnheart.org/about-cvd/the-burden-of-cvd/. Last accessed May 2024. |
6 Eurostat. Causes of death statistics. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Major_causes_of_death_in_the_EU_in_2020. Last accessed May 2024. |
7 European Heart Network. Fighting cardiovascular disease – a blueprint for EU action. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed May 2024. |
8 Daiichi Sankyo We Care for Every Heartbeat. European Survey Report of Cardiovascular Disease – Uncovering current public perceptions and attitudes towards cardiovascular disease. Available at: wecareforeveryheartbeat.com/wp-content/uploads/2023/08/European_Survey_Report_final_approved_Jul_2022.pdf. Last accessed May 2024. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520608896/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
